![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2004, European Molecular Biology Organization DNA damage induces downregulation of histone gene expression through the G1 checkpoint pathway 1Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA 2Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA 3Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA aDepartment of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA. Tel.: +1 585 273 1453; Fax: +1 585 273 1450; E-mail: jiyong_zhao/at/urmc.rochester.edu *Present address: Department of Parasitology, Wanjing Medical University, Wanjing, Jiangsu 210029, PR China Received June 25, 2003; Accepted December 8, 2003. This article has been cited by other articles in PMC.Abstract Activation of the G1 checkpoint following DNA damage leads to inhibition of cyclin E–Cdk2 and subsequent G1 arrest in higher eucaryotes. Little, however, is known about the molecular events downstream of cyclin E–Cdk2 inhibition. Here we show that, in addition to the inhibition of DNA synthesis, ionizing radiation induces downregulation of histone mRNA levels in mammalian cells. This downregulation occurs at the level of transcription and requires functional p53 and p21CIP1/WAF1 proteins. We demonstrate that DNA damage induced by ionizing radiation results in the suppression of phosphorylation of NPAT, an in vivo substrate of cyclin E–Cdk2 kinase and an essential regulator of histone gene transcription, and its dissociation from histone gene clusters in a p53/p21-dependent manner. Inhibition of Cdk2 activity by specific inhibitors in the absence of DNA damage similarly disperses NPAT from histone gene clusters and represses histone gene expression. Our results thus suggest that inhibition of Cdk2 activity following DNA damage results in the downregulation of histone gene transcription through dissociation of NPAT from histone gene clusters. Keywords: checkpoints, cyclin E–Cdk2, DNA damage, histone gene expression, NPAT Introduction To preserve the integrity of the genome, mammalian cells respond to DNA damage by activating checkpoint pathways. These pathways are crucial for cellular survival, and their perturbation can cause severe diseases including cancer (Zhou and Elledge, 2000; McGowan, 2002; Bartek and Lukas, 2003; Shiloh, 2003). Activation of the G1 checkpoint triggered by ionizing radiation (IR) requires the participation of a number of signaling molecules. Following IR, the tumor suppressor protein p53 is stabilized and activated through events initiated by ATM, a protein kinase whose gene is mutated in the human disease ataxia-telangiectasia (Kastan et al, 1992; Kuerbitz et al, 1992; Zhou and Elledge, 2000; Bartek and Lukas, 2003; Shiloh, 2003). p53 then induces the expression of the cyclin-dependent kinase (CDK) inhibitor p21, which binds to and inhibits the activities of cyclin E/A–Cdk2 kinases (El-Deiry et al, 1993; Gu et al, 1993; Harper et al, 1993; Xiong et al, 1993; Dulic et al, 1994). As cyclin E– and cyclin A–Cdk2 are required for S-phase entry (Fang and Newport, 1991; Girard et al, 1991; Tsai et al, 1993; van den Heuvel and Harlow, 1993; Jackson et al, 1995; Ohtsubo et al, 1995), DNA damage by IR thus induces a G1 arrest. Although the signaling pathways that lead to the inhibition of Cdk2 kinase have been extensively studied, the critical targets of this kinase that mediate the DNA damage response remain to be determined. Chromosome duplication during S phase of the eucaryotic cell cycle requires both replication of genomic DNA and the synthesis of histones, which are assembled with the newly synthesized DNA into chromatin fibers. In mammalian cells, the majority of histone synthesis occurs in S phase and is tightly coupled to the rate of DNA synthesis. The quantity of histones synthesized in mammalian cells is primarily determined by the abundance of histone mRNA, which in turn is controlled by multiple mechanisms including regulation of transcription, pre-mRNA processing and mRNA stability (Heintz, 1991; Osley, 1991; Stein et al, 1992; Marzluff and Duronio, 2002). We and others have previously shown that the cyclin E–Cdk2 substrate NPAT concentrates at a few nuclear foci that are associated with the histone gene clusters in vivo (Zhao et al, 1998, 2000; Ma et al, 2000). Ectopic expression of NPAT activates transcription of multiple histone promoter constructs as well as the endogenous histone genes ((Ma et al, 2000; Zhao et al, 2000; J Zhao et al, unpublished observations). This NPAT-mediated transcriptional activation is regulated by cyclin E–Cdk2-mediated phosphorylation (Ma et al, 2000; Zhao et al, 2000). Inhibition of NPAT expression by siRNA (Gao et al, 2003) impairs histone gene expression. Thus, NPAT is crucial for the activation of histone gene expression and links the cell cycle machinery to the regulation of histone synthesis. As histone synthesis is coupled with DNA synthesis during S phase, and histone gene transcription is regulated by the cyclin E–Cdk2 complex through NPAT phosphorylation, it is possible that DNA damage may also trigger downregulation of histone gene expression. We therefore investigated the regulation of histone gene expression after DNA damage by IR. In this study, we show that histone gene expression is downregulated, in parallel with the inhibition of DNA synthesis, upon IR. A deficiency for p53 or p21 alleviates this downregulation. In an effort to explore the underlying mechanism, we found that phosphorylation of NPAT is inhibited and the NPAT protein becomes dispersed from histone gene clusters after IR. We suggest that DNA damage induces downregulation of histone gene expression through inhibition of cyclin E–Cdk2 activity, which in turn interferes with NPAT function. Consistently, inhibition of Cdk2 activity with specific inhibitors in the absence of DNA damage also causes dissociation of NPAT protein from histone clusters, repression of histone gene expression and inhibition of entry into S phase. Thus, our results indicate that the G1 checkpoint regulates not only DNA synthesis but also histone gene expression. Moreover, these results identify the regulation of NPAT function as a downstream event of Cdk2 inhibition during the G1 checkpoint activation. Results DNA damage induces downregulation of histone gene expression To test directly whether DNA damage might cause decreased histone gene expression, we utilized HCT116 cells, a human colorectal cancer cell line that contains wild-type p53 and p21 genes and possesses an apparently normal G1 checkpoint (Waldman et al, 1995; Bunz et al, 1998). The cells were treated with IR, and the protein levels of p53 and p21, cyclin E and Cdk2 associated kinase activity and the histone mRNA levels before and after irradiation were analyzed. As reported previously (Waldman et al, 1995; Bunz et al, 1998), DNA damage caused by IR resulted in stabilization of p53, increased synthesis of the CDK inhibitor p21, inhibition of cyclin E and Cdk2 associated kinase activity and cell cycle arrest (Figure 1A–C
IR-induced repression of histone gene expression occurs in parallel with the inhibition of DNA synthesis Repression of histone gene expression after DNA damage may result indirectly from the inhibition of DNA synthesis, as it has previously been shown that sustained histone gene expression requires continued DNA synthesis (Heintz et al, 1983; Sittman et al, 1983; Baumbach et al, 1987). Alternatively, the inhibition of histone gene expression may be caused by a more direct DNA-damage-generated signaling event that is independent of DNA synthesis. To distinguish between these two possibilities, we analyzed cell cycle distribution and histone mRNA levels at multiple time points after IR, and compared the change in S-phase population with levels of histone mRNA abundance. IR caused increases in p53 and p21 proteins over time. By 6 h after irradiation, p21 protein levels had increased significantly, cyclin E–Cdk2 kinase activity had concomitantly decreased and a reduction of the S-phase population (BrdU-positive cells) was detectable at 8 h after irradiation (Figure 2A and B
p53 and p21 contribute to the downregulation of histone gene expression induced by ionizing radiation It has previously been shown that activation of the G1 checkpoint by IR requires functional p53 and p21 (Brugarolas et al, 1995; Deng et al, 1995; Waldman et al, 1995). To determine whether the inhibition of histone gene expression after IR also depends on these proteins, we employed mutant derivatives of the HCT116 cell line in which either the p53 gene or the p21 gene had been disrupted by homologous recombination (Waldman et al, 1995; Bunz et al, 1998). We analyzed how histone mRNA levels change in these cells after IR. As reported previously (Waldman et al, 1995; Bunz et al, 1998), IR does not cause G1-phase arrest in the p53- or p21-deficient HCT116 cells (data not shown, Figure 3B and D
DNA damage results in inhibition of histone gene transcription Next, we asked whether IR downregulates histone mRNA abundance at the level of transcription. We thus carried out nuclear run-on assays (Ausubel et al, 1991; Carey and Smale, 2000) using nuclei from γ-irradiated cells as well as from nonirradiated control cells, and compared the rate of histone gene transcription in these samples. While IR resulted in the inhibition of histone gene transcription in the parental HCT116 cells at 10 h following the treatment, this effect was essentially relieved in the p21-deficient HCT116 cells at the same time point (Figure 4
DNA damage induced by ionizing radiation results in the suppression of NPAT phosphorylation p21 protein interacts with CDKs and inhibits their activity (Gu et al, 1993; Harper et al, 1993; Xiong et al, 1993). The observation that inhibition of histone gene transcription following DNA damage requires functional p21 suggests that a CDK-controlled event is involved in this downregulation. The cyclin E–Cdk2 substrate NPAT associates with histone gene clusters in vivo and acts as a transcriptional regulator of histone genes (Zhao et al, 1998, 2000; Ma et al, 2000; Gao et al, 2003). It is thus possible that DNA damage induces downregulation of histone gene expression by modulating NPAT function. To investigate this possibility, we first examined the effect of IR on NPAT phosphorylation. It has previously been shown that NPAT is phosphorylated by cyclin E–Cdk2 both in vitro and in vivo (Ma et al, 2000; Zhao et al, 2000), and that phosphorylation of NPAT by cyclin E–Cdk2 at residues Ser 775 and Ser 779 causes a mobility shift of NPAT on SDS–PAGE gel (Ma et al, 2000). We employed a mobility shift assay to assess the phosphorylation state of NPAT after IR. While the majority of NPAT protein in growing HCT 116 cells was in the slower-migrating phosphorylated form, most (if not all) of the detectable NPAT protein converted to the unphosphorylated (faster-migrating form) after DNA damage (Figure 5
In contrast to the mobility changes of NPAT in the parental HCT 116 cells after IR, no such effect was observed in either p53−/− or p21−/− HCT116 cells (Figure 5 DNA damage causes dissociation of NPAT protein from histone gene clusters Having shown that the phosphorylation of NPAT is inhibited following DNA damage, we then asked whether IR has any effect on NPAT activity. NPAT protein concentrates at a few easily detectable nuclear foci that are associated with the histone gene clusters on chromosomes 1 and 6, and the association of NPAT with the histone gene clusters appears to be cell cycle dependent (Ma et al, 2000; Zhao et al, 2000; Zheng et al, 2003). We examined the localization of NPAT protein after exposing cells to IR. As shown in Figure 6A
Loss of the NPAT foci in γ-irradiated cells may result from a decrease of NPAT protein levels, as DNA damage induced cell cycle arrest and NPAT expression is cell cycle regulated (Zhao et al, 1998; Gao et al, 2003). Alternatively, NPAT protein may become dispersed after DNA damage. To distinguish between these two possibilities, we compared the NPAT protein levels in irradiated WI38 cells and control cells. IR caused induction of p21 protein, loss of NPAT foci and cell cycle arrest (Figure 6B and C Using chromatin immunoprecipitation (ChIP) assays, we have previously shown that NPAT protein associates with the histone promoters in vivo (Zhao et al, 2000). Loss of the NPAT foci following IR suggests that DNA damage causes dissociation of NPAT protein from the histone gene promoters. To test this notion directly, we examined the association of NPAT protein with a histone H4 promoter after irradiation using ChIP assays. As shown in Figure 6D As p53 and p21 are required for IR-induced downregulation of histone gene expression and inhibition of NPAT phosphorylation (Figures 3
Cdk2 activity is required for the formation of NPAT foci at histone gene clusters The finding that IR-induced suppression of NPAT phosphorylation and dispersion of NPAT protein from the histone gene loci requires functional p21 suggests that a CDK activity, which is inhibited following DNA damage, is required for NPAT to localize at histone gene clusters. As NPAT is an in vivo substrate of cyclin E–Cdk2 (Zhao et al, 1998, 2000; Ma et al, 2000), it is possible that the cyclin E–Cdk2 activity is required for NPAT foci formation. To test this hypothesis, we examined the effect of inhibition of cyclin E–Cdk2 on NPAT localization in transiently transfected cells. As shown in Figure 8A
To provide additional evidence that Cdk2 activity is required for NPAT to form the foci at histone gene clusters, we treated cells with the chemical inhibitor roscovitine at a concentration that specifically blocks Cdk2 but not Cdk4 and Cdk6 activity (Meijer et al, 1997), and examined its effect on NPAT localization. Consistent with the idea that Cdk2 activity is required for the NPAT foci formation, cells treated with roscovitine lost their NPAT foci, while treatment of cells with DMSO, the solvent for roscovitin, had no effect on NPAT localization (Figure 8B Induction of p21 represses histone gene expression concomitantly with the dissociation of NPAT protein from histone gene clusters The above results suggest that IR-induced downregulation of histone gene expression results from the suppression of NPAT phosphorylation and its dissociation from the histone gene promoters as a result of inhibition of cyclin E–Cdk2 by p21. If this suggestion is correct, one would predict that induction of p21 without γ-radiation should also inhibit histone gene expression. To test this idea directly, we generated a stable H1299 cell line that expresses p21 fused with the green fluorescent protein (GFP–p21) upon induction by doxycycline, and examined the effect of induction of the GFP–p21 on histone gene expression. These cells express very little GFP–p21 under noninducing conditions. Upon doxycycline induction, they express increasing amounts of GFP–p21 protein in a time-dependent manner (Figure 9A and B
Discussion In this study, we demonstrate that IR triggers p53/p21-dependent downregulation of histone gene expression at the level of transcription. Importantly, we show that IR, as well as inhibition of Cdk2 activity with specific inhibitors, results in the suppression of phosphorylation of the cyclin E–Cdk2 substrate NPAT and its dissociation from histone gene clusters. NPAT is crucial for histone gene transcription (Ma et al, 2000; Zhao et al, 2000; Gao et al, 2003), and association of NPAT protein with the histone gene clusters correlates with histone gene expression (this study). It is, therefore, likely that inhibition of histone gene transcription following IR results, at least in part, from the dissociation of NPAT protein from histone gene promoters. Thus, our studies have not only revealed that the G1 checkpoint regulates histone gene expression as well as DNA synthesis following IR, but have also identified regulation of NPAT function as a critical event downstream of Cdk2 inhibition (Figure 10
The results presented here support the idea that downregulation of histone gene expression following IR results directly from a DNA-damage-generated signal rather than indirectly from the inhibition of DNA synthesis. First, the decrease in histone mRNA levels following IR was observed slightly before a decrease in DNA synthesis (Figure 2D We and others have previously shown that cyclin E–Cdk2 regulates the function of NPAT in histone gene transcription (Ma et al, 2000; Zhao et al, 2000). However, the underlying mechanism has remained unclear. Our observations that NPAT becomes dissociated from histone promoters in response to the inhibition of Cdk2 activity by DNA damage or by various Cdk2 inhibitors suggest that phosphorylation of NPAT by cyclin E–Cdk2 is required for its association with histone gene clusters. Thus, one of the mechanisms by which cyclin E–Cdk2 controls NPAT function appears to be through regulating the interaction of NPAT with histone gene promoters. Consistently, it was recently reported that interaction of NPAT with both histone promoters and OCA-S, a coactivator essential for histone H2B transcription, occurs in an S-phase-dependent manner (Zheng et al, 2003). Our finding of a strong correlation between cyclin E–Cdk2 kinase activity, NPAT phosphorylation, the association of NPAT with histone gene clusters and histone gene expression provides additional support for the conclusion that phosphorylation of NPAT by cyclin E–Cdk2 is critical for histone gene expression. In this study, we have focused on investigating the effect of DNA damage inflicted by IR on histone gene expression. While treatment of cells with another DNA-damaging agent, adriamycin, also results in p53/p21-dependent downregulation of histone gene expression (Supplementary Figure 3), cisplatin apparently induces downregulation of histone gene expression via a p53/p21-independent pathway (data not shown). Thus, as for the regulation of DNA synthesis, multiple pathways exist in mammalian cells to downregulate histone gene expression in response to different forms of DNA lesions induced by various damaging agents. DNA replication and bulk histone synthesis are tightly coupled and appear to be mutually dependent during normal cell cycle progression (Heintz et al, 1983; Sittman et al, 1983; Baumbach et al, 1987; Ye et al, 2003). Perturbation of this association has deleterious consequences (Meeks-Wagner and Hartwell, 1986; Marzluff and Duronio, 2002). Recent studies indicate that chromatin assembly is also crucial for S-phase progression (Ye et al, 2003) and may also be inhibited by a DNA damage checkpoint pathway (Groth et al, 2003). Thus, mammalian cells have evolved mechanisms that ensure the tight coupling of DNA replication, histone gene expression and chromatin assembly under both normal growth conditions and conditions where DNA damage may occur. In addition to its role in histone gene transcription, expression of NPAT promotes G1 progression (Zhao et al, 1998; Gao et al, 2003). Recent studies suggest that the ability of NPAT to promote S-phase entry is independent of histone gene activation (Wei et al, 2003; J Zhao et al, unpublished observation). Inhibition of NPAT expression impeded progression at multiple phases of the cell cycle (Gao et al, 2003). Thus, NPAT functions in multiple cellular processes during cell cycle progression. Given the observations reported here and the requirement of NPAT for S-phase entry (Gao et al, 2003), one may speculate that regulation of NPAT function may also contribute to the inhibition of DNA synthesis following the activation of the G1 checkpoint in mammalian cells. Materials and methods Cell culture and generation of GFP–p21-inducible cell lines Primary human fibroblast WI38, MRC5 and human osteosarcoma U2OS cells were from American Type Culture Collection. Human colorectal cancer cell line HCT116 and p53- and p21-deficient HCT116 (Waldman et al, 1995; Bunz et al, 1998) were kindly provided by Dr Bert Vogelstein (The Johns Hopkins University School of Medicine). Human lung cancer cell line H1299 was from Dr Peter Keng (University of Rochester). WI38, MRC5, H1299 and U2OS cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), unless otherwise specified. HCT116 cells and their derivatives were cultured in McCoy's medium supplemented with 10% FBS. For synchronization of WI38 and MRC5, the cells were cultured in DMEM supplemented with 0.1% FBS for 3 days and then stimulated with 20% FBS (Zhao et al, 2000). To generate stable cell lines that express tetracycline-inducible GFP–p21 fusion protein, the human p21 cDNA was cloned into the pBIG2i vector (Strathdee et al, 1999). An in-frame fusion of p21 and enhanced green fluorescence protein (EGFP) was then made by inserting the EGFP sequence from the pEGFP-C1 plasmid (Clonetech) into the 5′ of the p21 sequence. The resulting pBIG2i EGFp21 plasmid was transfected into H1299 cells and stable clones were selected using 200 μg/ml hygromycin. Clones with inducible expression of GFP–p21 protein were initially selected by treating cells with 2 μg/ml doxycycline and screening for green fluorescence. Fluorescent colonies (EGFP–p21 H1299 cells) were picked and propagated in the absence of doxycycline. Plasmids and antibodies Plasmids pCMVneo, pCMVCdk2, pCMVCdk2dn, pCMVcyclinE, pCMVp21 and pCMVp27, the rabbit polyclonal antibody specific for NPAT and the mouse anti-cyclin E monoclonal antibodies were described previously (van den Heuvel and Harlow, 1993; LaBaer et al, 1997; Zhao et al, 2000). The rabbit polyclonal antibodies for p53, Cdk2 and β-tubulin were from Santa Cruz Biotechnology. The mouse anti-p21 antibody was from Upstate Biotechnology. The mouse monoclonal antibody specific for γ-tubulin was from Sigma. The mouse monoclonal antibody for GFP was from BD Biosciences Clontech. Transient transfection and immunofluorescence staining Transient transfections were carried out using FuGENE 6 (Roche) according to the protocol suggested by the manufacturer. U2OS cells were grown on glass coverslips placed in six-well plates and transfected with 500 ng expression plasmid plus 500 ng vector, or transfected with two expression plasmids, each 500 ng. To monitor the transfected cells, 50 ng pEGFP plasmid was also cotransfected. Immunofluorescence staining (IF) was carried out as described previously (Zhao et al, 2000). For quantitative analyses, the experiments were carried out independently at least twice, and more than 200 cells were analyzed in each experiment. Ionizing irradiation Cells were seeded 18–24 h prior to treatment unless otherwise specified and were irradiated with a 137Cs source. For irradiation of cells synchronized at G1 phase, cells were first arrested at G0 by serum starvation and then stimulated to enter the cell cycle as described above. At 4 h after serum addition, the cells were irradiated with a 137Cs source. Kinase assays Extracts prepared from HCT 116 cells at the indicated times after IR were incubated with antibodies specific for Cdk2 (M2) or cyclin E (HE111 and HE172). The immunoprecipitation was carried out as described previously (Zhao et al, 1998). Following immunoprecipitation, the immunoprecipitates were washed twice with a kinase reaction buffer (50 mM Tris–HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT and 0.1 mg/ml BSA), and incubated with 5 μg of histone H1 and 2 μCi of [γ-32P]ATP at 30°C for 20 min. The reaction was terminated with SDS–PAGE loading buffer, and phosphorylation of histone H1 was analyzed by autoradiography following SDS–PAGE. Lambda protein phosphatase treatment and NPAT mobility shift assays Extracts were prepared from parent, p21−/− or p53−/− HCT 116 cells before and after IR. NPAT protein in the extracts was immunoprecipitated using a mouse monoclonal antibody specific for NPAT. The immunoprecipitates were divided into two equal parts, and one part was treated with Lambda protein phosphatase (New England Biolabs) using the protocol suggested by the manufacturer. Both treated and untreated samples were separated by SDS–PAGE. The gel electrophoresis was carried out at 200 V for 2.5 h using a Bio-Rad Mini-Protein 3 cell. In order to detect the mobility shift of NPAT protein after irradiation, electrophoresis was carried out with a longer running time than usually used (2.5 h versus 40 min). Phosphorylated and unphosphorylatd forms of NPAT were analyzed on Western blots using a rabbit anti-NPAT antibody. Northern blot analysis and nuclear run-on assays Analysis of histone mRNA levels on Northern blots was carried out as described previously (Gao et al, 2003). The hybridization signals were quantitated using a phosphorimager (Bio-Rad) and normalized with the hybridization signal of GAPDH. Nuclear run-on assays were performed essentially as described (Ausubel et al, 1991), except that 32p-labelled RNA transcripts were isolated using a Qiagen RNeasy kit and hybridization were carried out at 55°C. Histone DNA prepared by PCR (Gao et al, 2003) and full-length human GAPDH cDNA were spotted onto Hybond N+ membrane (Amersham) using a dot-blot apparatus. The hybridization signals were quantitated using a phosphorimager (Bio-Rad) and normalized with the GAPDH signal. FACS analysis The cell cycle distribution before and after IR was determined using either propidium iodide (PI) staining or PI/BrdU double staining. FACS analysis using PI staining was carried out as described previously (Zhao et al, 1998). For the analysis using PI/BrdU double staining, BrdU (final concentration: 30 μM) was added to the culture medium 30 min before cells were harvested. The incorporation of BrdU was detected using a mouse anti-BrdU antibody (BD Biosciences) and an FITC-conjugated goat anti-mouse IgG antibody (Vector laboratories). Both DNA content and BrdU incorporation were analyzed by flow cytometry. Supplementary Figures: Click here to view.(1.3M, pdf) Acknowledgments We thank Hartmut Land for helpful discussions and critical reading of the manuscript, Bert Vogelstein for parental, p21−/− and p53−/− HCT116 cells, Peter Keng for H1299 cells and Catherine E Ovitt for preparation of the manuscript. This work is supported by NIH grant R01 GM065814 to JZ and by an award from the Howard Hughes Medical Institute to the University of Rochester School of Medicine and Dentistry under the Biomedical Research Support Program for Medical Schools. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Nature. 2000 Nov 23; 408(6811):433-9.
[Nature. 2000]Bioessays. 2002 Jun; 24(6):502-11.
[Bioessays. 2002]Cancer Cell. 2003 May; 3(5):421-9.
[Cancer Cell. 2003]Nat Rev Cancer. 2003 Mar; 3(3):155-68.
[Nat Rev Cancer. 2003]Cell. 1992 Nov 13; 71(4):587-97.
[Cell. 1992]Biochim Biophys Acta. 1991 Mar 26; 1088(3):327-39.
[Biochim Biophys Acta. 1991]Annu Rev Biochem. 1991; 60():827-61.
[Annu Rev Biochem. 1991]Curr Opin Cell Biol. 1992 Apr; 4(2):166-73.
[Curr Opin Cell Biol. 1992]Curr Opin Cell Biol. 2002 Dec; 14(6):692-9.
[Curr Opin Cell Biol. 2002]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2298-313.
[Genes Dev. 2000]Mol Cell Biol. 2003 Apr; 23(8):2821-33.
[Mol Cell Biol. 2003]Cancer Res. 1995 Nov 15; 55(22):5187-90.
[Cancer Res. 1995]Science. 1998 Nov 20; 282(5393):1497-501.
[Science. 1998]Mol Cell Biol. 1983 Apr; 3(4):539-50.
[Mol Cell Biol. 1983]Proc Natl Acad Sci U S A. 1983 Apr; 80(7):1849-53.
[Proc Natl Acad Sci U S A. 1983]Biochemistry. 1987 Sep 22; 26(19):6178-87.
[Biochemistry. 1987]Nat Genet. 2003 Jan; 33(1):80-4.
[Nat Genet. 2003]Nature. 1995 Oct 12; 377(6549):552-7.
[Nature. 1995]Cell. 1995 Aug 25; 82(4):675-84.
[Cell. 1995]Cancer Res. 1995 Nov 15; 55(22):5187-90.
[Cancer Res. 1995]Science. 1998 Nov 20; 282(5393):1497-501.
[Science. 1998]Nature. 1993 Dec 16; 366(6456):707-10.
[Nature. 1993]Cell. 1993 Nov 19; 75(4):805-16.
[Cell. 1993]Nature. 1993 Dec 16; 366(6456):701-4.
[Nature. 1993]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2298-313.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Cell. 2003 Jul 25; 114(2):255-66.
[Cell. 2003]FEBS Lett. 1994 Mar 14; 341(1):128-30.
[FEBS Lett. 1994]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Mol Cell Biol. 2003 Apr; 23(8):2821-33.
[Mol Cell Biol. 2003]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2298-313.
[Genes Dev. 2000]Nature. 1993 Dec 16; 366(6456):707-10.
[Nature. 1993]Cell. 1993 Nov 19; 75(4):805-16.
[Cell. 1993]Eur J Biochem. 1997 Jan 15; 243(1-2):527-36.
[Eur J Biochem. 1997]Genes Dev. 2000 Sep 15; 14(18):2298-313.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Mol Cell Biol. 2003 Apr; 23(8):2821-33.
[Mol Cell Biol. 2003]Mol Cell Biol. 1983 Apr; 3(4):539-50.
[Mol Cell Biol. 1983]Proc Natl Acad Sci U S A. 1983 Apr; 80(7):1849-53.
[Proc Natl Acad Sci U S A. 1983]Biochemistry. 1987 Sep 22; 26(19):6178-87.
[Biochemistry. 1987]Curr Opin Cell Biol. 2002 Dec; 14(6):692-9.
[Curr Opin Cell Biol. 2002]Genes Dev. 2000 Sep 15; 14(18):2298-313.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Cell. 2003 Jul 25; 114(2):255-66.
[Cell. 2003]Mol Cell Biol. 1983 Apr; 3(4):539-50.
[Mol Cell Biol. 1983]Proc Natl Acad Sci U S A. 1983 Apr; 80(7):1849-53.
[Proc Natl Acad Sci U S A. 1983]Biochemistry. 1987 Sep 22; 26(19):6178-87.
[Biochemistry. 1987]Mol Cell. 2003 Feb; 11(2):341-51.
[Mol Cell. 2003]Cell. 1986 Jan 17; 44(1):43-52.
[Cell. 1986]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Mol Cell Biol. 2003 Apr; 23(8):2821-33.
[Mol Cell Biol. 2003]Mol Cell Biol. 2003 May; 23(10):3669-80.
[Mol Cell Biol. 2003]Cancer Res. 1995 Nov 15; 55(22):5187-90.
[Cancer Res. 1995]Science. 1998 Nov 20; 282(5393):1497-501.
[Science. 1998]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Gene. 1999 Mar 18; 229(1-2):21-9.
[Gene. 1999]Science. 1993 Dec 24; 262(5142):2050-4.
[Science. 1993]Genes Dev. 1997 Apr 1; 11(7):847-62.
[Genes Dev. 1997]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Mol Cell Biol. 2003 Apr; 23(8):2821-33.
[Mol Cell Biol. 2003]Genes Dev. 1998 Feb 15; 12(4):456-61.
[Genes Dev. 1998]Genes Dev. 2000 Sep 15; 14(18):2283-97.
[Genes Dev. 2000]